Patient reported outcomes of MDD patients treated with esketamine nasal spray in real world practice: the French ELLIPSE study
P.-M. Llorca, L. Samalin, E. Olié, I. Rodriguez, J. Dupin, C. Wicart, P. DemaricourtIntroduction
Esketamine nasal spray (ESK) was approved in 2019 in Europe for adults with Treatment-Resistant Depression (TRD), defined as inadequate response to at least two different antidepressants during the current moderate to severe depressive episode
Objectives
To assess patient-reported outcomes related to symptomatology, quality of life, and occupational impairment over 12 months following ESK initiation in patients with Major Depressive Disorder (MDD)
Methods
ELLIPSE is a French, prospective, multicenter, non-interventional study describing MDD patients treated with ESK. Patient-reported outcomes were collected using QIDS-SR16, QLDS, and WPAI:D questionnaires throughout the 12-month follow-up (Baseline, D8, M1, M2, M3, M6, M9, M12).
Results
A total of 200 MDD patients (including 195 [97.5%] treatment resistant patients) were enrolled across 31 sites.
Among them, 108 (54.0%) were employed at baseline, including 79 on sick leave. The remaining 92 patients had no occupation at baseline, and 50 (25.0%) cited the current depressive episode as the reason, while 30 (15.0%) were retired.
QIDS response rates (improvement from baseline ≥ 50% or score ≤ 5) in patients treated with ESK increased to 37.7% at Month 2 (M2) and 45.0% at Month 3 (M3), then plateaued (Figure 1). QLDS response (improvement from baseline ≥ 8, (Rozjabek et al. 2022)) followed a similar trend, reaching 26.5% at M2 in patients undertreatment, with sustained response over the follow-up in both the total population and the patients still under treatment (Figure 2). WPAI:D scores showed consistent improvement across all four domains in patients still under treatment at the visit (Figure 3).
Image 1: Long description.